Gilead Sciences (NASDAQ:GILD) Price Target Raised to $145.00

Gilead Sciences (NASDAQ:GILD) had its target price lifted by TD Cowen from $125.00 to $145.00 in a report issued on Thursday morning,MarketScreener reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

GILD has been the topic of a number of other reports. Cantor Fitzgerald restated an “overweight” rating and set a $135.00 price target on shares of Gilead Sciences in a research report on Friday, October 31st. Sanford C. Bernstein set a $135.00 price objective on Gilead Sciences and gave the stock an “outperform” rating in a research note on Monday, December 29th. Weiss Ratings restated a “buy (b)” rating on shares of Gilead Sciences in a research note on Thursday, January 22nd. JPMorgan Chase & Co. upped their price target on shares of Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. Finally, Mizuho increased their price objective on shares of Gilead Sciences from $131.00 to $140.00 and gave the stock an “outperform” rating in a report on Friday, November 21st. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $136.73.

Gilead Sciences Stock Up 1.7%

Shares of NASDAQ:GILD opened at $141.95 on Thursday. The company’s fifty day moving average is $125.36 and its 200-day moving average is $119.67. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. Gilead Sciences has a 52 week low of $93.37 and a 52 week high of $142.20. The company has a market capitalization of $176.11 billion, a PE ratio of 22.01, a P/E/G ratio of 0.73 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.16 by $0.31. The firm had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The firm’s quarterly revenue was up 3.0% on a year-over-year basis. During the same period last year, the firm posted $2.02 EPS. Equities research analysts predict that Gilead Sciences will post 7.95 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Kelly A. Kramer sold 2,805 shares of the company’s stock in a transaction on Friday, November 28th. The shares were sold at an average price of $127.10, for a total value of $356,515.50. Following the completion of the transaction, the director directly owned 1,339 shares of the company’s stock, valued at approximately $170,186.90. This represents a 67.69% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction dated Wednesday, January 28th. The stock was sold at an average price of $139.89, for a total value of $1,398,900.00. Following the transaction, the chief executive officer owned 556,698 shares of the company’s stock, valued at approximately $77,876,483.22. This trade represents a 1.76% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 257,397 shares of company stock worth $33,385,512 in the last ninety days. 0.27% of the stock is owned by insiders.

Institutional Trading of Gilead Sciences

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Norges Bank bought a new stake in shares of Gilead Sciences during the 2nd quarter worth approximately $2,150,268,000. Ameriprise Financial Inc. increased its holdings in Gilead Sciences by 397.6% during the second quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company’s stock worth $748,147,000 after buying an additional 5,392,191 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in Gilead Sciences by 3,763.8% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company’s stock worth $518,368,000 after acquiring an additional 4,113,999 shares in the last quarter. Invesco Ltd. lifted its stake in Gilead Sciences by 33.5% in the second quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after acquiring an additional 3,394,330 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its position in shares of Gilead Sciences by 164.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 3,489,062 shares of the biopharmaceutical company’s stock valued at $387,286,000 after acquiring an additional 2,169,266 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Multiple sell‑side firms raised targets and reiterated bullish ratings (Wolfe Research to $155/outperform; TD Cowen to $145/buy), reinforcing buy-side momentum and implied upside from current levels. Read More. Read More.
• Positive Sentiment: Broader analyst upgrades/positive notes from Citi, Truist, BMO and UBS add to consensus bullishness, supporting demand and higher valuation multiples. Read More.
• Positive Sentiment: Clinical/regulatory wins for Trodelvy (added to NCCN guidelines; TNBC approval/win coverage) strengthen Gilead’s oncology growth story and revenue optionality beyond antivirals. Read More. Read More.
• Positive Sentiment: Coverage pieces noting that GILD has outperformed the market and is attracting analyst attention can draw momentum and ETF/quant flows into the stock. Read More.
• Neutral Sentiment: Notes on GILD’s presence in Nasdaq/healthcare ETF lineups and elevated investor attention increase volume and liquidity but are not clear directional catalysts by themselves. Read More.
• Negative Sentiment: Insider selling: CEO Daniel Patrick O’Day sold 10,000 shares (~$1.4M) at ~$139.89 (filed on Form 4). While modest relative to his remaining holding and potentially routine, insider sales can be interpreted negatively by some investors. Read More.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.